Currently, treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of patients with advanced lung cancer.1, 2 Only anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint blockers have significantly improved the prognosis of advanced lung cancer in clinical trials. This evidence concerns the gene CD274 and lung cancer.